Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Language
Year range
1.
Article | IMSEAR | ID: sea-199800

ABSTRACT

Background: To evaluate the effect of tamsulosin on blood glucose levels in euglycaemic rats and to investigate the effect of glibenclamide, tamsulosin and their combination on alloxan induced diabetic rats.Methods: Albino male wistar rats were randomly assigned into 6 groups (2 euglycaemic and 4 alloxan induced diabetic rats groups). In Euglycaemic rats either normal saline (0.5ml P.O) or tamsulosin (0.072mg/kg P.O) were given and blood glucose levels was estimated at 0 hr, 30min, 1hr, 2hr, 4hr on day 1 and at 0hr and 1hr on day 3 and day 7. Four groups of diabetic rats were given normal saline (0.5ml P.O), glibenclamide (5mg/kg P.O), tamsulosin (0.072mg/kg P.O), combination of glibenclamide and tamsulosin respectively and blood glucose levels were estimated on day 1, 3 and 7. Repeated measures ANOVA or paired 憈 憈est were used for within group comparison and one way ANOVA or unpaired 憈� test were used for between group comparison.Results: In euglycaemic rats tamsulosin caused significant rise in blood glucose levels at 1 hr on all days and in diabetic rats tamsulosin itself did not cause any significant alteration in blood glucose levels. However, its combination with glibenclamide delayed the onset of hypoglycemic effect of glibenclamide & also reduced its hypoglycemic effect.Conclusions: Tamsulosin significantly increase blood glucose level in euglycaemic rats and it interact with Glibenclamide to reduce its hypoglycemic activity in diabetic rats.

2.
Indian J Physiol Pharmacol ; 2012 Oct-Dec; 56(4): 367-374
Article in English | IMSEAR | ID: sea-146134

ABSTRACT

Introduction – Many drugs, including serratiopeptidases, are marketed without proven efficacy in clinical trials. It is protein in nature and claimed to be effective orally. Methods – 24 albino wistar rats, 6 each in following groups were assigned – (1) Control group (distilled water, orally) (2) Diclofenac (6.75 mg/kg, IP) (3) serratiopeptidase (5.4 mg/kg, orally) (4) Combination of serratiopeptidase (5.4 mg/kg, orally) and diclofenac (2.25 mg/kg, IP). Inflammatory agent, carrageenan (0.1 ml of 1% w/v) was injected subcutaneously in the ether anesthetized rat hind paw, half an hour after the administration of drug. Rat paw volume up to lateral malleolar process was recorded with plethysmometer at various time periods. Results – Percentage formation and inhibition of oedema in serratiopeptidase or combination groups were not significantly different than control group. Both were significantly less for diclofenac group. Conclusion – Serratiopeptidase was not effective in this animal model of oedema/inflammation.

SELECTION OF CITATIONS
SEARCH DETAIL